Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2'-deoxy-6-thioguanosine
2. Beta-2'-deoxythioguanosine
3. Beta-2'-deoxythioguanosine Mono-hydrate
4. Beta-thioguanine Deoxyriboside
1. 789-61-7
2. 6-thio-dg
3. Tgdr
4. Thioguanine Deoxyriboside
5. 6-thio-2'-deoxyguanosine
6. 2'-deoxy-6-thioguanosine
7. Beta-2'-deoxythioguanosine
8. 2'-desoxy-6-thioguanosine
9. 6-mercaptoguaninedeoxyriboside
10. Kr0rfb46df
11. Beta-thioguanidine Deoxyriboside
12. Beta-thioguanine Deoxyriboside
13. 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione
14. Beta-2'-deoxy-6-thioguanosine Monohydrate
15. Guanosine, 2'-deoxy-6-thio-
16. B-tgdr
17. 2'deoxy-6-thioguanosine
18. Thio
19. 2'-deoxy-6-thio Guanosine
20. Beta-2'-deoxythiol Guanosine
21. Ccris 195
22. Nsc71261
23. Nsc-71261
24. Thioguanine Deoxyriboside (van)
25. Thiodeoxyguanosine
26. Hsdb 7074
27. Beta-tgdr
28. 2-amino-9-(2-deoxy-beta-d-erythro-pentofuranosyl)-1,9-dihydro-6h-purine-6-thione
29. Nci-c01581
30. Thioguanine 9betad-2'-deoxyriboside
31. Brn 1224220
32. 6-thio-dg;
33. A-tgdr
34. Unii-kr0rfb46df
35. Schembl531274
36. Beta-thioguanosine Deoxyriboside
37. Schembl9634767
38. Chembl3250476
39. Dtxsid4021345
40. Mfcd00672275
41. S7757
42. Zinc17969618
43. Ccg-267279
44. Ac-32335
45. Hy-18762
46. Cs-0014289
47. 6-thio-2 Inverted Exclamation Marka-deoxyguanosine
48. 2-amino-9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-mercaptopurine
49. 2-amino-9-(2-deoxy-.beta.-d-erythropentofuranosyl)-9h-purine-6(1h)-thione
50. 9h-purine-6(1h)-thione, 2-amino-9-(2-deoxy-beta-d-erythro-pentofuranosyl)-
51. 2-amino-9-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purine-6(9h)-thione
52. 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1h-purine-6-thione
53. 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purine-6-thione
54. 30241-92-0
| Molecular Weight | 283.31 g/mol |
|---|---|
| Molecular Formula | C10H13N5O3S |
| XLogP3 | -0.8 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 283.07391047 g/mol |
| Monoisotopic Mass | 283.07391047 g/mol |
| Topological Polar Surface Area | 150 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 420 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
STUDIES SUGGEST THAT BETA-TGDR IS A LATENT FORM OF TG. SINCE RESISTANCE TO ANTILEUKEMIC AGENT 6-THIOGUANINE INEVITABLY DEVELOPS IN ANIMAL TUMORS, THIS NEW AGENT BETA-TGDR IS OF POTENTIAL CLINICAL USE.
LU K ET AL; PHARMACOKINETICS AND METABOLISM OF BETA-2'-DEOXYTHIOGUANOSINE AND 6-THIOGUANINE IN MAN; CANCER CHEMOTHER PHARMACOL 8 (1): 119-23 (1982)
THE PHARMACOKINETICS OF RADIOLABELED 6-THIOGUANINE (TG) WERE COMPARED WITH THAT OF BETA-2'-DEOXYTHIOGUANOSINE (BETA-TGDR) AFTER IV ADMIN. URINARY EXCRETION OF THE RADIOLABEL WAS 75% OF THE DOSE 24 HR AFTER ADMIN. BOTH THIOPURINES WERE RAPIDLY & EXTENSIVELY DEGRADED & EXCRETED AS 6-THIOXANTHINE, INORGANIC SULFATE, S-METHYL-6-THIOXANTHINE, & 6-THIOURIC ACID IN ADDITION TO OTHER PRODUCTS. SMALL AMOUNTS OF UNCHANGED DRUG WERE ALSO EXCRETED. STUDIES SUGGEST THAT BETA-TGDR IS A LATENT FORM OF TG. SINCE RESISTANCE TO ANTILEUKEMIC AGENT 6-THIOGUANINE INEVITABLY DEVELOPS IN ANIMAL TUMORS, THIS NEW AGENT BETA-TGDR IS OF POTENTIAL CLINICAL USE.
LU K ET AL; PHARMACOKINETICS AND METABOLISM OF BETA-2'-DEOXYTHIOGUANOSINE AND 6-THIOGUANINE IN MAN; CANCER CHEMOTHER PHARMACOL 8 (1): 119-23 (1982)
Drugs in Development
Details:
The net proceeds from the private placement will help the company to advance the clinical development of THIO -101 (ateganosine), which is being evaluated for 3L-NSCLC.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Regeneron Pharmaceuticals
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 27, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : $0.6 million
Deal Type : Private Placement
MAIA Biotechnology Announces Private Placement of Approximately $695,000
Details : The net proceeds from the private placement will help the company to advance the clinical development of THIO -101 (ateganosine), which is being evaluated for 3L-NSCLC.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2025
Details:
The net proceeds from the private placement will help the company to advance the clinical development of THIO -101 (ateganosine), which is being evaluated for 3L-NSCLC.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Regeneron Pharmaceuticals
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 01, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : $1.0 million
Deal Type : Private Placement
MAIA Biotechnology Announces $1.08 Million Private Placement
Details : The net proceeds from the private placement will help the company to advance the clinical development of THIO -101 (ateganosine), which is being evaluated for 3L-NSCLC.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2025
Details:
Undisclosed
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2025
Details:
THIO (ateganosine) is a telomere-targeting agent currently in clinical development in combination with a checkpoint inhibitor for third line non-small cell lung cancer.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAIA Wins USAN Approval for “Ateganosine” as THIO’s Nonproprietary Name
Details : THIO (ateganosine) is a telomere-targeting agent currently in clinical development in combination with a checkpoint inhibitor for third line non-small cell lung cancer.
Product Name : THIO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2025
Details:
THIO(6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with a checkpoint inhibitor for third line non-small cell lung cancer.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAIA to Start Phase 3 THIO Trial in Advanced Non-Small Cell Lung Cancer
Details : THIO(6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with a checkpoint inhibitor for third line non-small cell lung cancer.
Product Name : THIO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2025
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAIA Expands THIO-101 Phase 2 Trial in Non-Small Cell Lung Cancer
Details : THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Product Name : THIO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2025
Details:
The Company intends to use the combined net proceeds to fund the starting cost for Part C of the Phase 2 THIO-101 clinical trial evaluating THIO (6-Thio-2'-Deoxyguanosine).
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 24, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.4 million
Deal Type : Private Placement
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
Details : The Company intends to use the combined net proceeds to fund the starting cost for Part C of the Phase 2 THIO-101 clinical trial evaluating THIO (6-Thio-2'-Deoxyguanosine).
Product Name : THIO
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 24, 2025
Details:
The net proceeds from the offering for to fund research and development activities, such as THIO-101 (6-Thio-2-Deoxyguanosine) for the treatment of patients with non-small cell lung cancer.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 18, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $2.7 million
Deal Type : Private Placement
MAIA Biotechnology Announces Private Placement of $2,715,000
Details : The net proceeds from the offering for to fund research and development activities, such as THIO-101 (6-Thio-2-Deoxyguanosine) for the treatment of patients with non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 18, 2025
Details:
THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Lead Product(s): Ateganosine,Cemiplimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Regeneron Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 04, 2025
Lead Product(s) : Ateganosine,Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
MAIA Updates on Positive Phase 2 THIO-101 Trial in Advanced NSCLC
Details : THIO-101 (6-Thio-2-Deoxyguanosine) is a telomere-targeting agent currently in clinical development in combination with cemiplimab for non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2025
Details:
FDA has designated THIO (6-thio-2-deoxyguanosine) for the treatment of pediatric-type diffuse high-grade gliomas, as it has shown to activate the immune system while evading tumor immunosuppression.
Lead Product(s): Ateganosine,Inapplicable
Therapeutic Area: Oncology Brand Name: THIO
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024
Lead Product(s) : Ateganosine,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO in Gliomas
Details : FDA has designated THIO (6-thio-2-deoxyguanosine) for the treatment of pediatric-type diffuse high-grade gliomas, as it has shown to activate the immune system while evading tumor immunosuppression.
Product Name : THIO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
11 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/11/3148625/0/en/MAIA-Biotechnology-Highlights-Positive-Efficacy-Data-from-THIO-101-Phase-2-Clinical-Trial-in-Non-Small-Cell-Lung-Cancer.html
05 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/05/3145282/0/en/MAIA-Biotechnology-Abstract-Selected-for-Poster-Presentation-at-2025-IASLC-World-Conference-on-Lung-Cancer.html
28 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250728212094/en/MAIA-Biotechnology-Receives-FDAs-Fast-Track-Designation-for-Ateganosine-as-a-Treatment-for-Non-Small-Cell-Lung-Cancer
01 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250401656979/en/MAIA-Biotechnology-CEO-Details-Anticipated-Clinical-Milestones-for-Novel-Cancer-Immunotherapy-in-2025-Letter-to-Shareholders
ABOUT THIS PAGE
61
PharmaCompass offers a list of Ateganosine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ateganosine manufacturer or Ateganosine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ateganosine manufacturer or Ateganosine supplier.
PharmaCompass also assists you with knowing the Ateganosine API Price utilized in the formulation of products. Ateganosine API Price is not always fixed or binding as the Ateganosine Price is obtained through a variety of data sources. The Ateganosine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ateganosine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ateganosine, including repackagers and relabelers. The FDA regulates Ateganosine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ateganosine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ateganosine supplier is an individual or a company that provides Ateganosine active pharmaceutical ingredient (API) or Ateganosine finished formulations upon request. The Ateganosine suppliers may include Ateganosine API manufacturers, exporters, distributors and traders.
Ateganosine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ateganosine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ateganosine GMP manufacturer or Ateganosine GMP API supplier for your needs.
A Ateganosine CoA (Certificate of Analysis) is a formal document that attests to Ateganosine's compliance with Ateganosine specifications and serves as a tool for batch-level quality control.
Ateganosine CoA mostly includes findings from lab analyses of a specific batch. For each Ateganosine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ateganosine may be tested according to a variety of international standards, such as European Pharmacopoeia (Ateganosine EP), Ateganosine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ateganosine USP).
Share 
